This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (131)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

S. Roth, MD; N. Agrawal, MD; M. Mahowald, MD; H. Montoya, MD; D. Robbins, MD; S. Miller, MD; E. Nutting, PhD; E. Woods, MSEd; M. Crager, PhD; C. Nissen; E. Swabb, MD, PhD

Arch Intern Med. 1989;149(4):775-779.

Abstract
• High-dose aspirin therapy for rheumatoid arthritis is frequently associated with severe gastrointestinal injury. To explore the possibility of reversing such damage, we conducted a double-blind, multicenter study with misoprostol, a prostaglandin E1 analog, which has demonstrated mucosal protective, gastric antisecretory, and ulcer healing properties. We also studied possible interference of misoprostol with continuing aspirin treatment in the management of patients with rheumatoid arthritis. Patients with confirmed rheumatoid arthritis and endoscopically documented gastroduodenal lesions were randomly assigned to receive 200 µg of misoprostol four times a day (123 patients) or placebo (116 patients). Each concurrently received 650 to 1300 mg of aspirin four times a day. After eight weeks of treatment, misoprostol was statistically superior to placebo in healing gastric mucosal injury (70% vs 25%) and duodenal mucosal injury (86% vs 53%). Patients with gastric or duodenal ulcers on admission had superior ulcer healing rates with misoprostol (67% vs 26%). There was no evidence of interference with the antirheumatic properties of aspirin. Mild to moderate adverse experiences were equally noted in misoprostol and placebo groups. Misoprostol, coadministered with aspirin, is well tolerated and highly effective in healing aspirin-associated gastroduodenal lesions in patients with rheumatoid arthritis without altering the therapeutic benefits of aspirin.

(Arch Intern Med 1989;149:775-779)

Author Affiliations
From the Arthritis Center Ltd, Phoenix (Dr Roth); Tulane University School of Medicine, New Orleans (Dr Agrawal); Veterans Administration Medical Center, Minneapolis (Dr Mahowald); Winona Memorial Hospital, Indianapolis (Dr Montoya); Division of Rheumatology/Allergy, University of California, Davis (Dr Robbins); and the G. D. Searle and Company, Skokie, Ill (Drs Miller, Nutting, Crager, Swabb, and Messrs Woods and Nissen).

Footnotes
Accepted for publication Oct 3, 1988.

Reprint requests to Arthritis Center Ltd, 3330 N Second St, No. 601, Phoenix, AZ 85012 (Dr Roth).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Aspirin, like all other drugs, is a poison
Tramèr
BMJ 2000;321:1170-1171.
FULL TEXT  

NSAID Gastropathy: A New Understanding
Roth
Arch Intern Med 1996;156:1623-1628.
ABSTRACT  

Rational use of NSAIDs for musculoskeletal disorders
DTB 1994;32:91-95.
ABSTRACT | FULL TEXT  

Effects of Nonsteroidal Anti-inflammatory Drugs on Endogenous Gastrointestinal Prostaglandins and Therapeutic Strategies for Prevention and Treatment of Nonsteroidal Anti-inflammatory Drug--Induced Damage
Cryer and Feldman
Arch Intern Med 1992;152:1145-1155.
ABSTRACT  

Nonsteroidal Anti-inflammatory Drugs and Peptic Ulcer Disease
Soll et al.
ANN INTERN MED 1991;114:307-319.
ABSTRACT